Prothena Corporation plc 0Y3M.L Stock
Prothena Corporation plc Price Chart
Prothena Corporation plc 0Y3M.L Financial and Trading Overview
Prothena Corporation plc stock price | 22.88 USD |
Previous Close | 70.68 USD |
Open | 0 USD |
Bid | 0 USD x N/A |
Ask | 0 USD x N/A |
Day's Range | 0 - 0 USD |
52 Week Range | 0 - 79.16 USD |
Volume | 507 USD |
Avg. Volume | 132 USD |
Market Cap | 23.75M USD |
Beta (5Y Monthly) | 0.360211 |
PE Ratio (TTM) | 0.54167414 |
EPS (TTM) | 1.34 USD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
0Y3M.L Valuation Measures
Enterprise Value | 3.16B USD |
Trailing P/E | 0.54167414 |
Forward P/E | N/A |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 0.4325112 |
Price/Book (mrq) | 6.313503 |
Enterprise Value/Revenue | 57.52 |
Enterprise Value/EBITDA | -21.177 |
Trading Information
Prothena Corporation plc Stock Price History
Beta (5Y Monthly) | 0.360211 |
52-Week Change | 166.11% |
S&P500 52-Week Change | 20.43% |
52 Week High | 79.16 USD |
52 Week Low | 0 USD |
50-Day Moving Average | 61.33 USD |
200-Day Moving Average | 53.69 USD |
0Y3M.L Share Statistics
Avg. Volume (3 month) | 132 USD |
Avg. Daily Volume (10-Days) | 57 USD |
Shares Outstanding | 39.86M |
Float | 38.68M |
Short Ratio | N/A |
% Held by Insiders | 4.72% |
% Held by Institutions | 95.09% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | N/A |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | -232.19% |
Operating Margin (ttm) | -273.0069% |
Gross Margin | -178.68% |
EBITDA Margin | -271.61% |
Management Effectiveness
Return on Assets (ttm) | -14.16% |
Return on Equity (ttm) | -24.37% |
Income Statement
Revenue (ttm) | 54.92M USD |
Revenue Per Share (ttm) | 1.13 USD |
Quarterly Revenue Growth (yoy) | 88.09% |
Gross Profit (ttm) | -81657000 USD |
EBITDA | -149175008 USD |
Net Income Avi to Common (ttm) | -127523000 USD |
Diluted EPS (ttm) | 1.344 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 686.18M USD |
Total Cash Per Share (mrq) | 13.01 USD |
Total Debt (mrq) | 4.89M USD |
Total Debt/Equity (mrq) | 0.8 USD |
Current Ratio (mrq) | 14.327 |
Book Value Per Share (mrq) | 11.531 |
Cash Flow Statement
Operating Cash Flow (ttm) | -118864000 USD |
Levered Free Cash Flow (ttm) | -42870248 USD |
Profile of Prothena Corporation plc
Country | United Kingdom |
State | N/A |
City | Dublin |
Address | 77 Sir John Rogerson’s Quay |
ZIP | 2 |
Phone | 353 1 236 2500 |
Website | https://www.prothena.com |
Industry | |
Sector(s) | |
Full Time Employees | 127 |
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease and other related synucleinopathies; NNC6019 that completed Phase I clinical trial for the treatment of ATTR amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease, as well as TDP-43 and PRX019 for the treatment of Alzheimer's disease and other neurodegenerative diseases. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.
Q&A For Prothena Corporation plc Stock
What is a current 0Y3M.L stock price?
Prothena Corporation plc 0Y3M.L stock price today per share is 22.88 USD.
How to purchase Prothena Corporation plc stock?
You can buy 0Y3M.L shares on the LSE exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Prothena Corporation plc?
The stock symbol or ticker of Prothena Corporation plc is 0Y3M.L.
How many shares does Prothena Corporation plc have in circulation?
The max supply of Prothena Corporation plc shares is 326.29K.
What is Prothena Corporation plc Price to Earnings Ratio (PE Ratio)?
Prothena Corporation plc PE Ratio is 0.17023809 now.
What was Prothena Corporation plc earnings per share over the trailing 12 months (TTM)?
Prothena Corporation plc EPS is 1.34 USD over the trailing 12 months.